

COMPANY PROFILE

STRATEC designs and manufactures fully automated analyzer systems and smart consumables on the basis of its own patented technologies for its partners in clinical diagnostics and the life sciences industry. The company also provides sample preparation solutions and integrated laboratory software for these applications.

STRATEC can draw on a wealth of experience and an extensive technology pool to offer its partners automation and instrumentation technologies and solutions, as well as software development and sample preparation services.

Its services include joint definition of specifications, the entire development process, production, quality assurance, and preparations for approval by the relevant authorities in the target markets. Both existing technologies and newly developed solutions are consistently adapted in terms of their design to conform to partners' own corporate design schemes.

SHARE CHART



SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	41.47%
Treasury shares	0.06%
Institutional investors	36.72%
Retail investors including not identified institutional investors	21.75%
Total	100.00%

MANAGEMENT BOARD



Marcus Wolfinger



Dr. Robert Siegle



Dr. Claus Vielsack

SUPERVISORY BOARD

> Fred K. Brückner

> Rainer Baule

> Prof. Dr. Stefanie Remmele

STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	DAXsector All Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Capital stock	11,913,445 Euro
No. of shares	11,913,445
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

FINANCIAL CALENDAR

Oct 26, 2017	Publication Quarterly Statement (call-date Q3)
Nov 28, 2017	Analysts' Conference

ANNUAL FIGURES

IFRS (in € million)	2012	2013	2014	2015	2016
Sales	122.7	128.0	144.9	146.9	184.9
EBIT	15.6	19.5	24.1	26.9	32.3
EBIT as % of sales	12.7	15.2	16.6	18.3	17.5
Consolidated net income	12.5	15.5	19.8	22.1	25.4
Basic earnings per share (in €)	1.06	1.32	1.68	1.87	2.14
Dividend per share (in €)	0.56	0.60	0.70	0.75	0.77
Total employees	533	546	544	583	976
Total assets	108.5	117.8	137.8	158.9	258.0
Equity ratio (in %)	80.7	82.5	81.3	82.0	55.7
Free cash flow	0.4	13.5	32.9	17.3	-

QUARTERLY FIGURES

IFRS (in € thousand)	2017		2016			2015		
	Q1	Q1	H1	9M	Q1	H1	9M	
Sales	49,510	31,218	78,032	126,334	34,547	70,012	107,200	
EBIT ¹	6,870	4,530	12,616	18,391	5,840	11,986	19,235	
EBIT as % of sales ¹	13.9	14.5	16.2	14.6	16.9	17.1	17.9	
Consolidated net income ²	5,369	3,424	10,312	15,251	4,739	9,807	15,916	
Basic earnings per share (in €) ²	0.45	0.29	0.87	1.29	0.40	0.83	1.35	

¹ 2017 figure adjusted for one-off items resulting from transaction activities and related reorganization expenses

² 2017 figure additionally adjusted for financing expenses and tax expenses in connection with the acquisitions of the Diatron Group and STRATEC Consumables

STRATEC Biomedical AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

Investor Relations

Phone: +49 7082 7916-991
Fax: +49 7082 7916-999
ir@stratec.com